Progress in Neurotherapeutics and Neuropsychopharmacology

Progress in Neurotherapeutics and Neuropsychopharmacology 2008

Jeffrey L. Cummings a1c1
a1 Departments of Neurology and Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Email:

Article author query
cummings jl   [PubMed][Google Scholar] 


There has been continuous progress in neurotherapeutics and neuropsychopharmacology in the past year. Notable are the reports of successful preliminary disease-modifying trials in Niemann-Pick disease and Friedreich's ataxia. Progress also has been made in treatment of migraine, stroke, epilepsy, multiple sclerosis, traumatic brain injury, and pain. Biomarkers are increasingly used to establish proof of pharmacology including measures of cerebrospinal fluid constituents and brain changes on magnetic resonance imaging. There is an increasing diversity of patient populations participating in clinical trials, including pediatric migraine and traumatic brain injury.

Key Words: argatroban; atorvastatin; biomarkers; bipolar depression; clinical trials; deep brain stimulation; depression; disease modification; duloxatine; epilepsy; fingolimod; Friedreich's ataxia; glatiramer acetate; Huntington's disease; Idebenone; methylphenidate; miglustat; migraine; modafinil; multiple sclerosis; neuropathic pain; nicardipine; Niemann-Pick Type C disease; Parkinson's disease; pharmacogenetics; pregabalin; retigabin; riluzole; ritogitine; rivastigmine; rizatripan; schizophrenia; spinal cord injury pain; testosterone; tramiprosate; transcranial magnetic stimulation; traumatic brain injury; zolmitriptan; zonisamide..

c1 Correspondence should be addressed to: Jeffrey L. Cummings, MD, UCLA Alzheimer Disease Center, 10911 Weyburn Ave., Suite 200, Los Angeles, CA 90095, USA; Ph: +1 310 794 3665; Fax: +1 310 794 3148; Email: